REGENXBIO (RGNX) SEC Filings: History & Chart

REGENXBIO Inc.(RGNX)

Biotechnology · Rockville, MD

$7.62-0.14 (-1.77%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

About REGENXBIO Inc.

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.

Rockville, MD

371 employees

www.regenxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Curran Simpson

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
3	Aug 27, 2026	Aug 27, 2026	View filing
8-K	Aug 25, 2026	Aug 25, 2026	View filing
8-K	Aug 24, 2026	Aug 24, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Jul 20, 2026	Jul 20, 2026	View filing
424B5	Jul 17, 2026	Jul 17, 2026	View filing
FWP	Jul 17, 2026	Jul 16, 2026	View filing
424B5	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
SC TO-I/A	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
SC TO-I/A	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jun 29, 2026	Jun 29, 2026	View filing
SC 13G/A	Jun 4, 2026	Jun 4, 2026	View filing
SC TO-I	Jun 3, 2026	Jun 3, 2026	View filing
8-K	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing

SEC Filings

Recent Filings